ezyvast 25 mg filmsko obložene tablete
krka, d.d., novo mesto - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan
ezyvast 25 mg filmsko obložene tablete
krka, d.d., novo mesto - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan
ezyvast 25 mg filmsko obložene tablete
krka, d.d., novo mesto - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan
ezyvast 25 mg filmsko obložene tablete
krka, d.d., novo mesto - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan
ezyvast 25 mg filmsko obložene tablete
krka, d.d., novo mesto - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan
gynodian depot 4 mg/200 mg raztopina za injiciranje
bayer pharma ag - estradiolvalerat; prasteronenantat - raztopina za injiciranje - estradiolvalerat 4 mg / 1 ml prasteronenantat200 mg / 1 ml; prasteronenantat 200 mg / 1 ml - prasteron in estrogen
firmagon
ferring pharmaceuticals a/s - degareliks - prostatične neoplazme - endokrini terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
faslodex
astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.
panretin
eisai gmbh - alitretinoin - sarcoma, kaposi - antineoplastična sredstva - panretin gel je navedena za lokalno zdravljenje kožne lezije pri bolnikih s pridobljenim-imunski-pomanjkljivosti-sindrom (aids), povezanih z kaposi ' s sarkom (ks), če:so poškodbe, ki niso ulcerated ali lymphoedematous, in;zdravljenje globokih ks, ni potrebno, in;poškodbe se ne odziva na sistemski antiretrovirusne terapije, in;naprave za radioterapijo ali kemoterapijo niso primerne.
forsteo
eli lilly nederland b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - kalcij homeostaza - zdravljenje osteoporoze pri ženskah po menopavzi in pri moških z večjim tveganjem zloma. pri ženskah v postmenopavzi je bilo dokazano znatno zmanjšanje pojavnosti vretenc in nevretenčnih zlomov, ne pa zlomov kolka. zdravljenje osteoporoze, povezane s trajno sistemsko glukokortikoidnih terapija pri ženskah in moških na povečano tveganje za zlom.